Editas Medicine Files 8-K Report
Ticker: EDIT · Form: 8-K · Filed: Oct 9, 2025 · CIK: 1650664
Sentiment: neutral
Topics: sec-filing, regulatory-disclosure
TL;DR
Editas Medicine filed an 8-K on Oct 9, 2025. Details pending.
AI Summary
On October 9, 2025, Editas Medicine, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Other Events, along with Financial Statements and Exhibits. No specific financial figures or material events beyond the filing itself were detailed in the provided text.
Why It Matters
This 8-K filing indicates that Editas Medicine, Inc. has submitted a regulatory document to the SEC, which may contain important updates for investors.
Risk Assessment
Risk Level: low — The filing is a standard 8-K submission and does not, in itself, indicate any immediate material risks.
Key Players & Entities
- Editas Medicine, Inc. (company) — Registrant
- October 9, 2025 (date) — Date of earliest event reported
- 11 Hurley Street Cambridge, Massachusetts 02141 (address) — Principal Executive Offices
FAQ
What is the primary purpose of this 8-K filing by Editas Medicine, Inc.?
The 8-K filing is for Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits.
When was the earliest event reported in this filing?
The earliest event reported is dated October 9, 2025.
What is the principal executive office address for Editas Medicine, Inc.?
The principal executive offices are located at 11 Hurley Street, Cambridge, Massachusetts 02141.
What is the Commission File Number for Editas Medicine, Inc.?
The Commission File Number is 001-37687.
What is the IRS Employer Identification Number for Editas Medicine, Inc.?
The IRS Employer Identification Number is 46-4097528.
Filing Stats: 720 words · 3 min read · ~2 pages · Grade level 12.2 · Accepted 2025-10-09 16:31:21
Key Financial Figures
- $0.0001 — ange on which registered Common Stock, $0.0001 par value per share EDIT The Nasdaq Sto
Filing Documents
- edit-20251009.htm (8-K) — 28KB
- esgct_datareleasexfinal.htm (EX-99) — 15KB
- image_0.jpg (GRAPHIC) — 10KB
- 0001650664-25-000148.txt ( ) — 187KB
- edit-20251009.xsd (EX-101.SCH) — 2KB
- edit-20251009_def.xml (EX-101.DEF) — 3KB
- edit-20251009_lab.xml (EX-101.LAB) — 23KB
- edit-20251009_pre.xml (EX-101.PRE) — 14KB
- edit-20251009_htm.xml (XML) — 3KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On October 9, 2025, Editas Medicine, Inc. (the "Company") issued a press release titled "Editas Medicine Reports In Vivo Proof-of-Concept Data for EDIT-401 at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress," a copy of which is furnished as Exhibit 99.1 hereto. The information in this Item 7.01, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
01 Other Events
Item 8.01 Other Events. On October 9, 2025, at the 32nd Annual European Society of Gene and Cell Therapy Congress, the Company reported in vivo preclinical proof-of-concept data for EDIT-401, an experimental, potential best-in-class, one-time therapy to significantly reduce LDL-cholesterol ("LDL-C") through upregulation of the LDL receptor ("LDLR"). In preclinical studies in non-human primates, EDIT-401 achieved LDL-C reductions in non-human primates equal to or exceeding 90% within 48 hours of a single dose. EDIT-401 also achieved LDL-C reductions equal to or exceeding 90% in mice with high baseline LDL-C and reduced LDLR function. LDL-C reductions were maintained in mouse models in a three-month study. The Company's EDIT-401 therapeutic strategy includes the use of a CRISPR/Cas9 nuclease and dual guide RNAs with lipid nanoparticle delivery to disrupt negative regulatory elements in the 3' UTR, increasing mRNA stability enabling potent LDLR upregulation. The Company observed that the LDL-C reductions following EDIT-401 treatment were achieved with an at least six-fold mean increase in LDLR protein in the non-human primate liver, requiring only a moderate level of functional editing of LDLR alleles.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release issued by the Company on October 9, 2025* 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) * This exhibit shall be deemed to be furnished and not filed.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. EDITAS MEDICINE, INC. Date: October 9, 2025 By: /s/ Amy Parison Amy Parison Chief Financial Officer